Archive

Tiara and Reducer Featured at CSI Frankfurt 2018

NASDAQ, TSX: NVCN VANCOUVER, July 2, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TZX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that its Tiara™ ("Tiara"), a transcatheter treatment of mitral valve disease, and the...

Read More

Tiara™ Featured in Live Case at 11th Annual TVT 2018

NASDAQ, TSX: NVCN VANCOUVER, June 21, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that its Tiara™ ("Tiara") transcatheter mitral valve replacement device was featured in a...

Read More

Neovasc Announces First Implant of a Neovasc Reducer™ in a U.S. Patient

NASDAQ, TSX: NVCN VANCOUVER, June 20, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced the first U.S. patient has been implanted with a Neovasc Reducer™ (the "Reducer"),...

Read More

Neovasc’s Management and Board of Directors Urge Shareholders to Vote In Favor of the Proposed Reverse Stock Split at the Upcoming Annual General and Special Meeting of Shareholders

NASDAQ, TSX: NVCN VANCOUVER, May 15, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that its management and board of directors (the "Board") urge the Company's shareholders...

Read More